H1n1, Inovio Biomedical Corporation | featured news

Inovio Biomedical H1N1 Influenza DNA Vaccines Demonstrate 100% Responses Against Swine Flu in Vaccinated Pigs

Inovio Biomedical Corporation , a leader in DNA vaccine design, development and delivery, announced today that the company's SynCon™ H1N1 influenza DNA vaccines achieved protective antibody responses against H1N1 swine influenza virus in 100% of pigs immunized with a two-dose vaccine regimen.

 

Subscribe to this RSS topic: Syndicate content